En savoir plus
Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.
Table des matières
1. An introduction to CRISPR-Cas systems for reprogramming of the genome of mammalian cells
2. CRISPR-Cas systems for genome editing of mammalian cells
3. Genome-wide detection and analysis of CRISPR-Cas off-targets
4. CRISPR-based diagnostics for detection of pathogens
5. Creating cell lines for mimicking diseases
6. Modulating Cas9 activity for precision gene editing
7. Crispr-Cas9 in cancer therapeutics
8. CRISPR-Cas9 for treating heredity diseases
9. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
10. Recent advances in stem cells & gene editing: Drug discovery and therapeutics
11. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms
12. Genome editing in cardiovascular diseases
13. CRISPR/Cas9 in epigenetics studies of health and disease
14. Patents, ethics, biosafety and regulation using CRISPR technology
A propos de l'auteur
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.
